Immatics operates as a biopharmaceutical company in the clinical phase, focusing on the exploration and advancement of T-cell redirecting immunotherapies for addressing cancer. Our revolutionary potential treatments include top-notch Adoptive Cell Therapies and TCR Bispecific molecules TCER™, targeting tumor features identified and confirmed through our exclusive XPRESIDENT® technology. Our aim is to bring the effectiveness of T-cell redirecting immunotherapies to individuals battling cancer.